A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT
A Phase III, Multicenter, Open-label, Randomized Controlled Clinical Study on the Treatment of Locally Advanced Cervical Cancer With Cadonilimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
378 participants
Apr 24, 2026
INTERVENTIONAL
Conditions
Summary
This study mainly evaluated the efficacy and safety of Cadonilimab combined with chemotherapy followed by concurrent chemoradiotherapy versus standard concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
EBRT: 45-50.4Gy, Brachytherapy: 7Gy×4 or 6Gy ×5
Cisplatin 40mg/m2, qw×5
Cadonilimab （Moderate dose）+ albumin paclitaxel 90mg/m2, qw×6+ cisplatin 25mg/m2, qw×6
EBRT: 45-50.4Gy; Brachytherapy: 6Gy×4
cisplatin 25mg/m2, qw×5
Cadonilimab （Moderate dose）×9 or half a year
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07400536